(MASS) 908 Devices - Ratings and Ratios
Mass, Spec, Analyzer, Device, Platform
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 78.8% |
| Value at Risk 5%th | 109% |
| Relative Tail Risk | -15.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.21 |
| Alpha | 162.11 |
| CAGR/Max DD | -0.12 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.596 |
| Beta | 0.979 |
| Beta Downside | 0.136 |
| Drawdowns 3y | |
|---|---|
| Max DD | 84.85% |
| Mean DD | 46.77% |
| Median DD | 46.41% |
Description: MASS 908 Devices October 28, 2025
908 Devices Inc. (NASDAQ:MASS) is a commercial-stage technology firm headquartered in Boston that designs and sells purpose-built handheld and desktop mass-spectrometry instruments for life-science research, bioprocessing, pharma/biopharma, forensics and related markets.
Its flagship products include the MX908 handheld mass spectrometer for rapid identification of solids, liquids, vapors and aerosols; the Rebel desktop analyzer that delivers real-time extracellular environment data for bioprocesses; and the Maverick optical in-line analyzer that monitors glucose, lactate, biomass and generates fingerprint data to support predictive bioprocess modeling. Complementary offerings such as Maven (online bioprocess monitoring), Trace C2 (methanol/ethanol feed control), and the ZipChip plug-and-play high-resolution separation platform round out the portfolio.
Recent financials show FY 2023 revenue of roughly $28 million, up about 42 % year-over-year, with a gross margin near 70 % and cash and equivalents of $45 million, giving the company a runway of over 18 months at current burn rates. The global mass-spectrometry market is projected to grow at a 7 % CAGR through 2030, driven by expanding biologics pipelines, tighter regulatory demands for real-time release testing, and increasing adoption of continuous biomanufacturing-trends that directly benefit 908 Devices’ core addressable market.
For a deeper quantitative dive into MASS’s valuation and peer benchmarks, the ValueRay platform provides a granular, data-driven analysis you may find useful.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-4.13m TTM) > 0 and > 6% of Revenue (6% = 3.46m TTM) |
| FCFTA -0.15 (>2.0%) and ΔFCFTA 2.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 179.5% (prev 174.2%; Δ 5.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.14 (>3.0%) and CFO -27.2m <= Net Income -4.13m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.49 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (36.1m) change vs 12m ago 4.13% (target <= -2.0% for YES) |
| Gross Margin 49.35% (prev 52.57%; Δ -3.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 31.23% (prev 26.79%; Δ 4.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.85 (EBITDA TTM -37.5m / Interest Expense TTM 14.8m) >= 6 (WARN >= 3) |
Altman Z'' -6.24
| (A) 0.54 = (Total Current Assets 144.9m - Total Current Liabilities 41.5m) / Total Assets 190.9m |
| (B) -1.19 = Retained Earnings (Balance) -227.5m / Total Assets 190.9m |
| warn (B) unusual magnitude: -1.19 — check mapping/units |
| (C) -0.23 = EBIT TTM -42.3m / Avg Total Assets 184.6m |
| (D) -4.17 = Book Value of Equity -227.4m / Total Liabilities 54.6m |
| Total Rating: -6.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 23.01
| 1. Piotroski 0.50pt |
| 2. FCF Yield -32.24% |
| 3. FCF Margin -49.28% |
| 4. Debt/Equity 0.03 |
| 5. Debt/Ebitda 1.56 |
| 6. ROIC - WACC (= -39.70)% |
| 7. RoE -2.96% |
| 8. Rev. Trend 20.87% |
| 9. EPS Trend -38.27% |
What is the price of MASS shares?
Over the past week, the price has changed by -10.12%, over one month by -13.19%, over three months by -34.60% and over the past year by +150.23%.
Is MASS a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MASS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10 | 87.6% |
| Analysts Target Price | 10 | 87.6% |
| ValueRay Target Price | 5.3 | 0.2% |
MASS Fundamental Data Overview December 25, 2025
P/S = 3.0103
P/B = 1.5747
Beta = 0.464
Revenue TTM = 57.6m USD
EBIT TTM = -42.3m USD
EBITDA TTM = -37.5m USD
Long Term Debt = 4.35m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 481.0k USD (from shortTermDebt, last quarter)
Debt = 4.35m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -58.4m USD (from netDebt column, last quarter)
Enterprise Value = 88.1m USD (195.8m + Debt 4.35m - CCE 112.1m)
Interest Coverage Ratio = -2.85 (Ebit TTM -42.3m / Interest Expense TTM 14.8m)
FCF Yield = -32.24% (FCF TTM -28.4m / Enterprise Value 88.1m)
FCF Margin = -49.28% (FCF TTM -28.4m / Revenue TTM 57.6m)
Net Margin = -7.17% (Net Income TTM -4.13m / Revenue TTM 57.6m)
Gross Margin = 49.35% ((Revenue TTM 57.6m - Cost of Revenue TTM 29.2m) / Revenue TTM)
Gross Margin QoQ = 52.52% (prev 48.89%)
Tobins Q-Ratio = 0.46 (Enterprise Value 88.1m / Total Assets 190.9m)
Interest Expense / Debt = 340.2% (Interest Expense 14.8m / Debt 4.35m)
Taxrate = -0.19% (negative due to tax credits) (29.0k / -14.9m)
NOPAT = -42.3m (EBIT -42.3m * (1 - -0.19%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.49 (Total Current Assets 144.9m / Total Current Liabilities 41.5m)
Debt / Equity = 0.03 (Debt 4.35m / totalStockholderEquity, last quarter 136.3m)
Debt / EBITDA = 1.56 (negative EBITDA) (Net Debt -58.4m / EBITDA -37.5m)
Debt / FCF = 2.06 (negative FCF - burning cash) (Net Debt -58.4m / FCF TTM -28.4m)
Total Stockholder Equity = 139.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.16% (Net Income -4.13m / Total Assets 190.9m)
RoE = -2.96% (Net Income TTM -4.13m / Total Stockholder Equity 139.8m)
RoCE = -29.32% (EBIT -42.3m / Capital Employed (Equity 139.8m + L.T.Debt 4.35m))
RoIC = -30.29% (negative operating profit) (NOPAT -42.3m / Invested Capital 139.8m)
WACC = 9.41% (E(195.8m)/V(200.2m) * Re(9.62%) + (debt cost/tax rate unavailable))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.49%
Fair Price DCF = unknown (Cash Flow -28.4m)
EPS Correlation: -38.27 | EPS CAGR: -12.13% | SUE: -1.15 | # QB: 0
Revenue Correlation: 20.87 | Revenue CAGR: -3.23% | SUE: 0.26 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.09 | Chg30d=-0.020 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.26 | Chg30d=-0.035 | Revisions Net=-1 | Growth EPS=+23.5% | Growth Revenue=+19.6%
Additional Sources for MASS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle